Pluristem to Present Promising PLX Data for Additional Clinical Indications at Prestigious International Conference on Regenerative Medicine
BUSINESS WIRE
Posted: 2007-10-11 08:55:35
NEW YORK--(BUSINESS WIRE)----Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, degenerative and auto-immune indications, announced today that it will present favorable results of pre-clinical studies of its proprietary PLacental eXpanded (PLX) cells for additional clinical indications on October 18th, at the "3rd World Congress on Regenerative Medicine" in Leipzig, Germany.
The Company previously announced that it had obtained favorable results in pre-clinical testing of PLX cells to treat limb ischemia, a potential market of over $1 Billion. PLX cells also showed in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson's Disease.
Mr. Zami Aberman, Pluristem Chairman and CEO commented, "We are very proud that the Congress' organizing committee found our research and studies valuable and chose Pluristem to present its findings at the Congress. We strongly believe that our PLX cells can be used to treat other diseases, such as central nervous system and cardiovascular disorders. We will soon submit the IND for our first product, PLX-I, for the treatment of blood cancers, to begin clinical trials early next year in the USA."
About the "3rd World Congress on Regenerative Medicine"
On October 18-20, 2007 in Leipzig, Germany, the 3rd World Congress on Regenerative Medicine (WCRM), internationally renowned scientists from several countries will present the newest results of their research. Stem cells, umbilical cord cells, bone and cartilage regeneration, immunology, skin and tissue regeneration as well as tissue engineering, bioreactors and imaging are themes for plenary lectures and it is expected that fruitful discussions and a general exchange of experience will take place between science and industry. The Congress is organized by the Fraunhofer Institute for Cell Therapy and Immunology. Additionally, the World Congress is accompanied by an extensive industrial trade fair, which makes direct communication possible between representatives from science and industry. regmed.org
About Pluristem
Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.
Pluristem has offices in the USA with research and manufacturing facilities in Israel. www.pluristem.com |
